Workflow
脑起搏器(DBS)
icon
Search documents
没有手抖,也可能是帕金森?
Hu Xiu· 2025-10-16 08:12
得了帕金森病就一定会手抖吗?还有什么症状可以帮助早期发现?除了药物,还有什么治疗手段?干细 胞、基因疗法,这些对帕金森病有效吗? 本期,我邀请到了复旦大学附属华山医院神经内科主任,帕金森病顶尖专家王坚教授,分享他从医三十 多年中的故事,听过他细致的讲述和叮嘱,你会发现,原来帕金森真的没那么可怕! 菠萝:王教授,帕金森病患者是真的越来越多了吗? 王坚教授:是的,现在一个大的趋势就是人口老龄化,与之密切相关的就是神经退行性的疾病,包括阿 尔兹海默症、帕金森病等等,患病率也越来越高。再加上医疗资源的不平衡,大医院的专家门诊和专病 门诊,确实是人满为患。 菠萝:您和帕金森病打交道多少年了? 王坚教授:确切的讲是31年了。最近一位患者说,王医生,30年前你帮我确诊的,这些年,我有问题都 是来找你。我一下子意识到,自己也算是不知不觉中变成一个"老"医生了。 菠萝:现在您对帕金森病的理解和31年前有什么不一样吗? 王坚教授:31年前我刚来华山读研究生的时候,研究课题就是帕金森,跟今天确实大不一样。当时这个 领域里有一个非常重要的研究进展,就是PET显像示踪剂的使用,通俗来讲,就是拍一种特殊的PET的 片子,和普通CT或磁共 ...
研判2025!中国神经调节行业产业链、市场规模及重点企业分析:以精准神经调控革新治疗范式,重塑患者生活质量新标准[图]
Chan Ye Xin Xi Wang· 2025-10-10 01:33
Core Insights - Neuromodulation technology shows significant advantages in treating neurological diseases such as epilepsy and Parkinson's disease, enhancing treatment effectiveness and improving patients' quality of life [1][8] - The Chinese neuromodulation industry is projected to reach a market size of approximately 2.285 billion yuan in 2024, reflecting a year-on-year growth of 8.65%, driven by technological innovation and market demand [1][8] Industry Overview - Neuromodulation is a treatment method that regulates nervous system activity through electrical, magnetic, chemical, or other forms of stimulation, aiming to alleviate symptoms and improve functionality [2] - The industry can be categorized into invasive and non-invasive techniques, each comprising various specific technologies [2] Industry Development History - The Chinese neuromodulation industry has evolved over seventy years, starting from foundational research in the 1950s to the current stage of mature expansion, with significant milestones in technology introduction and innovation [2][3] - Key developments include the first DBS surgery in 1998 and the establishment of the first domestic DBS product registration in 2013, marking a shift from technology importation to independent innovation [2][3] Market Size - The neuromodulation market is expected to grow to approximately 2.285 billion yuan in 2024, with an 8.65% increase from the previous year, indicating a dual driving effect of technology transformation and market demand [1][8] Key Companies - Beijing Pincai Medical holds over 25% of the domestic market share with its comprehensive range of neuromodulation products, including DBS and SCS [9][10] - Suzhou Jingyu Medical is a leading player in the DBS field, having received FDA breakthrough device designation for its dual-target DBS technology [10][11] Industry Development Trends 1. Continuous integration of technological innovations will drive precision and intelligent upgrades in the neuromodulation sector, with advancements in AI and brain-computer interfaces expected to enhance treatment efficacy [12] 2. Application scenarios are expanding from traditional disease treatment to cognitive enhancement and emotional regulation, with consumer-grade neuromodulation devices anticipated to see explosive growth [13][14] 3. Policy and industry collaboration will promote domestic production and global expansion, with ongoing government support for brain science initiatives and the inclusion of neuromodulation procedures in insurance reimbursement [15]